Artivion, Inc. (NYSE:AORT) Receives $49.11 Consensus Price Target from Analysts

Artivion, Inc. (NYSE:AORT) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $49.1143.

A number of equities research analysts have recently commented on AORT shares. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Wall Street Zen cut shares of Artivion from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, January 21st. Needham & Company LLC restated a “buy” rating and issued a $58.00 price target on shares of Artivion in a research note on Monday, February 2nd. Finally, Citizens Jmp increased their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th.

Insider Buying and Selling

In related news, CAO Amy Horton sold 4,572 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $44.42, for a total value of $203,088.24. Following the transaction, the chief accounting officer directly owned 130,058 shares in the company, valued at approximately $5,777,176.36. This represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jean F. Holloway sold 7,315 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $45.30, for a total transaction of $331,369.50. Following the completion of the sale, the senior vice president owned 156,093 shares in the company, valued at approximately $7,071,012.90. This trade represents a 4.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 196,243 shares of company stock worth $8,889,334 in the last quarter. 8.10% of the stock is owned by insiders.

Institutional Trading of Artivion

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after buying an additional 141,030 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Artivion by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 998,327 shares of the company’s stock worth $45,542,000 after purchasing an additional 66,709 shares during the period. Bank of America Corp DE grew its stake in shares of Artivion by 22.8% during the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after purchasing an additional 119,634 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Artivion by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock valued at $24,510,000 after purchasing an additional 317,518 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Artivion by 40.8% in the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock valued at $14,960,000 after purchasing an additional 139,370 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Stock Up 2.0%

Shares of AORT opened at $40.40 on Friday. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -168.33 and a beta of 1.59. Artivion has a 52 week low of $21.97 and a 52 week high of $48.25. The stock’s 50-day moving average price is $43.97 and its 200-day moving average price is $42.79. The company has a quick ratio of 2.88, a current ratio of 3.93 and a debt-to-equity ratio of 0.50.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.